Ocuphire Pharma PE Ratio 2010-2024 | IRD

Current and historical p/e ratio for Ocuphire Pharma (IRD) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Ocuphire Pharma PE ratio as of October 24, 2024 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Ocuphire Pharma PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-10-24 1.13 0.00
2024-06-30 1.53 $-0.55 0.00
2024-03-31 2.01 $-0.49 0.00
2023-12-31 3.01 $-0.48 0.00
2023-09-30 3.35 $1.31 2.56
2023-06-30 4.34 $0.84 5.17
2023-03-31 3.75 $0.83 4.52
2022-12-31 3.53 $0.76 4.64
2022-09-30 2.01 $-1.17 0.00
2022-06-30 1.92 $-1.20 0.00
2022-03-31 3.24 $-1.47 0.00
2021-12-31 3.73 $-4.69 0.00
2021-09-30 5.15 $-4.34 0.00
2021-06-30 5.28 $-4.09 0.00
2021-03-31 5.81 $-6.05 0.00
2020-12-31 6.49 $-3.08 0.00
2020-09-30 8.32 $-3.08 0.00
2020-06-30 11.36 $-5.04 0.00
2020-03-31 7.20 $-5.00 0.00
2019-12-31 7.64 $-6.88 0.00
2019-09-30 8.20 $-10.72 0.00
2019-06-30 20.64 $-16.92 0.00
2019-03-31 24.48 $-20.25 0.00
2018-12-31 44.64 $-21.13 0.00
2018-09-30 85.44 $-21.61 0.00
2018-06-30 67.68 $-15.37 0.00
2018-03-31 72.48 $-8.16 0.00
2017-12-31 96.96 $-48.02 0.00
2017-09-30 116.16 $-43.70 0.00
2017-06-30 137.28 $-46.58 0.00
2017-03-31 244.80 $-52.82 0.00
2016-12-31 68.11 $-19.21 0.00
2016-09-30 100.80 $-28.81 0.00
2016-06-30 120.58 $-33.61 0.00
2016-03-31 158.45 $-38.42 0.00
2015-12-31 174.24 $-38.42 0.00
2015-09-30 249.60 $-33.61 0.00
2015-06-30 291.70 $-28.81 0.00
2015-03-31 350.40 $-19.21 0.00
2014-12-31 336.00 $-52.82 0.00
2014-09-30 388.80 $-52.82 0.00
2014-06-30 417.60 $-57.62 0.00
2014-03-31 518.40 $-72.03 0.00
2013-12-31 244.80 $-33.61 0.00
2013-09-30 218.35 $-28.81 0.00
2013-06-30 213.12 $-19.21 0.00
2013-03-31 146.40 $-4.80 0.00
2012-12-31 148.80 $-9.60 0.00
2012-09-30 242.40 $-9.60 0.00
2012-06-30 153.60 $-19.21 0.00
2012-03-31 254.40 $-48.02 0.00
2011-12-31 180.48 $-62.43 0.00
2011-09-30 480.00 $-105.64 0.00
2011-06-30 595.20 $-110.45 0.00
2011-03-31 566.40 $-100.84 0.00
2010-12-31 537.60 $-86.43 0.00
2010-09-30 556.80 $-52.82 0.00
2010-06-30 686.40 $-48.02 0.00
2010-03-31 777.60 $-43.22 0.00
2009-12-31 326.40 $-48.02 0.00
Sector Industry Market Cap Revenue
$0.000B $0.000B
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
Stock Name Country Market Cap PE Ratio
Fanhua (AIFU) China $0.086B 2.07
Top KingWin (WAI) China $0.008B 0.00
S&W Seed (SANW) United States $0.006B 0.00
Invo BioScience (NAYA) United States $0.004B 0.00